Table 2.
Demographic, clinical, and biochemical data of hemodialysis patients at baseline (T0) and at each time point: after 7 weeks of treatment with synbiotic or placebo (T7w), and after the eighth week of treatment with synbiotic or placebo combined with innovative dialysis (T8w). BHD: Bicarbonate Hemodialysis; DVB-PVP HD: DVB-PVP-cartridge hemodialysis; sCr: serum creatinine; CRP: C-reactive protein. * p < 0,05 DVB HD vs. BHD; § p < 0.05 DVB HD vs. Baseline (Wilcoxon signed rank test).
| Patients Data | Study Population | Controls | ||||
|---|---|---|---|---|---|---|
| Baseline (T0) | BHD (T7w) |
DVB-PVP HD (T8w) |
Baseline (T0) |
BHD (T7w) |
DVB-PVP HD (T8w) |
|
| Patients treated with Synbiotic (n = 6) | Patients treated with Placebo (n = 5) | |||||
| Age, years | 56 ± 7 | 52 ± 5 | ||||
| Male, n(%) | 5 (83%) | 4 (80%) | ||||
| SCr, mg/dL | 8.5 ± 1.2 | 8.1 ± 1.5 | 8.4 ± 1.1 | 9.4 ± 1.5 | 8.5 ± 2.4 | 7.5 ± 2.7§ |
| Albumin, g/dL | 3.6 ± 0.4 | 3.7 ± 0.2 | 3.3 ± 0.4* | 3.4 ± 0.4 | 3.3 ± 0.4 | 3.0 ± 0.3*,§ |
| Azotemia mg/dL | 132 ± 44 | 125 ± 20 | 114 ± 19 | 120 ± 33 | 114 ± 42 | 100 ± 54 |
| Glycemia, mg/dL | 51 ± 19 | 48 ± 30 | 79 ± 16*,§ | 72 ± 12 | 80 ± 20 | 84 ± 23 |
| CPR mg/L | 6.4 ± 5.1 | 3.1 ± 0.4 | 5.8 ± 3.9 | 10 ± 14 | 10 ± 9 | 10 ± 7 |